• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT® (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT® technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

  • FOCUSEDONATTENTION

    Learn more about how KemPharm® is applying their LAT® technology to create improved ADHD therapies. See the pipeline page for information on the research and development of prodrugs.

Products & Possibilities

Our co-lead clinical development candidates are KP415 – a prodrug product of dexmethylphenidate (d-MPH) with potential improvements over existing extended-release ADHD treatments, and KP484 – a “super-extended release” d-MPH prodrug product for the treatment of ADHD in patients that require a very long duration of therapy.

In addition, we have gained approval of Apadaz®, an immediate-release, benzhydrocodone/acetaminophen combination product for the treatment of acute pain. 

Our Value Proposition

KemPharm® believes that its LAT® technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s pipeline consists of multiple programs targeting opportunities in ADHD, pain, and CNS indications.

We employ our LAT® (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

Learn more about LAT®

July 21, 2021

Featured Publication

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

Celebration, FL – July 21, 2021 – KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the U.S. commercial launch of AZSTARYS™, a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture

  • 10

    Nov

    21

  • KemPharm Reports Third Quarter 2021 Financial...

  • 05

    Nov

    21

  • KemPharm Announces AZSTARYS® Clin...

  • 03

    Nov

    21

  • KemPharm to Report Third Quarter 2021 Results